Metoclopramide Removal during Continuous Ambulatory Peritoneal Dialysis

Metoclopramide Therapy and Movement Disorders in a Diabetic–Uremic Subject With Bilateral Basal Ganglia Lesions

“…In addition, a significant proportion of the total body clearance of metoclopramide depends on adequate renal function, the half-life is markedly prolonged in chronic renal failure, 11 and the clearance of metoclopramide by CAPD is negligible because of its high molecular weight and large volume of distribution. 12 We speculated that metoclopramide therapy may further damage the vulnerable basal ganglia and lead to drug-induced parkinsonism and also the syndrome of acute bilateral basal ganglia lesions in this diabeticeuremic subject.…”